SCHEMBL19627604

SCHEMBL19627604

C[C@H]1CN(C(=O)OC(C)(C)C)CCC1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.48
EPHX1 P07099 1/20 0.48
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GPR119 Q8TDV5 3/20 0.44
NR1H2 P55055 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
KDM4E B2RXH2 1/20 0.43
THRB P10828 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
USP30 Q70CQ3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2904961 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2924319 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL17286040 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL17286034 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL4560509 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL30521367 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2924321 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL1549896 1.00 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL31080706 0.90 MEN1 (0.53) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL31080651 0.90 MEN1 (0.53) HPGDRECQLEPHX1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B HPGD 2207/4885RECQL 3360/4885EPHX1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.